Ab-CPP-LSP-siRNA-Cy3 (ARC; cetuximab–PEG–LMWP–AANL–siRNA)
Sequence: VSRRRRGGRRRRRRAANL
siRNA (anti-EGFP; thiol-modified; Cy3/TAMRA labeled variants used for imaging)
| Experiment Id | EXP001980 |
|---|---|
| Paper | Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker me |
| Peptide | Ab-CPP-LSP-siRNA-Cy3 (ARC; cetuximab–PEG–LMWP–AANL–siRNA) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | Covalent ARC. |
| Formulation Format | Targeted enzyme-activatable antibody–peptide–siRNA conjugate |
| Formulation Components | Ab-CPP-LSP-siRNA-Cy3 administered IV. |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Athymic BALB/c nude mice with subcutaneous HCT116-EGFP xenograft tumors (~100 mm³) |
| Administration Route | IV tail vein; 1 mg/kg siRNA every 3 days ×4; analysis 3 days after 4th dose |
| Output Type | In vivo functional RNA delivery (tumor EGFP downregulation) + tumor siRNA accumulation |
| Output Value | EGFP downregulation ~66.7% (western blot); fluorescence-based analysis reports ~89.1% inhibition. |
| Output Units | |
| Output Notes | Highest tumor Cy3 signal among groups; strongest in vivo knockdown. |
| Toxicity Notes | |
| Curation Notes |